Sana Biotechnology Inc【SANA】株式ニュース

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Sana Biotechnology to Present at June 2026 Investor Conferences

SEATTLE, May 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on...

Form 8-K - Current report

Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility

SEATTLE , May 15, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates

Announced strategic collaboration with Mayo Clinic, focused on improving care in type 1 diabetes and...

Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference

SEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on...

Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting

SEATTLE, April 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on...

👍️0

HANUMAN 2月前

SANA now linked with Mayo, both financially and for development. Couldn't have a better partner.
https://www.tipranks.com/news/company-announcements/sana-biotechnology-secures-strategic-equity-investment-from-mayo

👍️0

glenn1919 2月前

SANA..............................https://stockcharts.com/sc3/ui/?s=SANA&p=w&b=5&g=0&id=p86431144783

👍️0

glenn1919 2月前

SANA..................................a/h

👍️0

runncoach 4月前

It is interesting technology. Really hope they can get some more people enrolled , and we can get a better idea

👍 1

HANUMAN 4月前

It is amazing that this transplant has been working for a year now using unmatched islet cells and NO immune suppression. Admittedly, P-1 has not finished recruiting, but when they can report survivorship of more than one patient, this will explode.

👍️0

HANUMAN 4月前

SANA news from 2 weeks ago:
Sana Biotechnology, Inc. (the “Company” or “Sana”) intends to discuss an updated corporate presentation (the “Corporate Presentation”) at the 44th Annual J.P. Morgan
Healthcare Conference on January 14, 2026. A copy of the Corporate Presentation is furnished as Exhibit 99.1 to this Current Report
Company’s programs and platforms, including the following:
• At 12 months post-transplantation into a patient with type 1 diabetes who received no immunosuppression, UP421, a primary pancreatic islet cell therapy
engineered with Sana’s hypoimmune platform (“HIP”) technology, continued to survive, evade immune detection, and function.
• Sana remains on track to file an investigational new drug application (“IND”) and begin a Phase 1 trial for SC451, a HIP-modified, induced pluripotent stem cell
(“iPSC”)-derived pancreatic islet cell therapy, as early as this year.
• Sana announced its goal of generating initial human data as early as this year for SG293, an in vivo CD19-directed CAR T cell therapy.

Healthy lifestyle will help type 2 DM, but without insulin and type 1, you will die at a young age. Study human physiology.

👍️0

November61 6月前

Eating balanced meals (counting carbs), exercising regularly, managing stress, getting enough sleep will help anyone with type 1 diabetes.

Too many BioScams are milking the market.

👍️0

runncoach 6月前

Exactly. Just because most of these are longshots doesn't mean they are scams. Just don't invest more than one can afford to lose is what I say.

👍️0

HANUMAN 6月前

If you had type 1 diabetes, you would care.

👍️0

November61 6月前

Who cares, they just sell shares for their research.

The system allows that, and they milk as much as they can.

Potential shareholders need to be prudent. Trading, not investing, imo.

👍️0

HANUMAN 6月前

Bioscams don't get their work published in peer reviewed journals.

👍 1

November61 6月前

Another BioScam in the making.

Additional upcoming data from early clinical trials for SC451, a stem-cell derived therapy for type 1 diabetes, which is in preclinical development but targeting future clinical readouts.

👍 1

tw0122 6月前

upcoming clinical data readouts that could impact SANA's (Sana Biotechnology, Inc.) https://www.perplexity.ai/finance/SANA price targets include
Data from the Phase 1 GLEAM trial evaluating SC291, a CD19-directed allogeneic CAR T cell therapy for autoimmune diseases, which Sana expects to share in 2025

👍 1

tw0122 6月前

analyst rating of "Strong Buy" from multiple firms, with 11 analysts providing price targets as of late October 2025. The average price target is around $8.70, with the highest target at $15.00 and the lowest at $5.00. The most recent analyst ratings were issued by Citizens, Wedbush, and Morgan Stanley, with targets ranging from $5.00 to $8.00 and $12.00.?

👍️0

tw0122 6月前

, a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in December. The presentations will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer.The webcasts will be accessible on the Investor Relations page of Sana’s website at https://www.globenewswire.com/Tracker?data=j1CZt8aJ3vRIzQKEKkKsvwyGOhmoySrB6li90vptNVrR4yd0q6Gg8zFx78pqHwU5adT3eFQ2yRBfXg7ioNgxNg==. A replay of each presentation will be available at the same location for 30 days following the conference.
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, WA, Cambridge, MA, and South San Francisco, CA. For more information about Sana Biotechnology, please

EMJ Capital President Eric Jackson on Wednesday expressed optimism about Sana Biotechnology (SANA) stock, saying it could become “the next 100-bagger platform.”

SANA shares traded 35% higher at the time of writing.

Jackson took to the social media platform X, opining that SANA stock would eventually explode, and highlighted the company’s various achievements, including its work in type 1 diabetes treatment. In January, Sana said that following a transplant of an allogeneic primary islet cell therapy into a patient with type 1 diabetes, they started producing insulin. The therapy was engineered with Sana’s hypoimmune (HIP) technology, enabling the transplantation without the need for immunosuppression.

👍 1

runncoach 8月前

Right. I mean it may not work , but it does have monster potential. Hope it isn't too good to be true

👍️ 1

HANUMAN 8月前

Also, the capability of removing the autoimmune factor opens up multiple other applications.

👍 1

runncoach 8月前

Thanks. It's certainly an interesting speculative risk/reward stock

👍️0

HANUMAN 8月前

A Seeking Alpha analyist called it a hundred bagger.

👍️0

runncoach 8月前

Any idea why the move?

👍️0

maddog27 8月前

Blind squirrel....
9/23/25 09:37:06 BOT +5 SANA 100 17 OCT 25 5 CALL .05 -3.25 -5.00 36,842.73

👍️0

HANUMAN 9月前

Yes, I was aware of that.

👍️0

FooBarAndGrill 9月前

Singular Keyword: Patient

Reread yesterday's PR, 2nd paragraph.

👍️0

Zadie420 10月前

Ok. What phase are we? On the Web site said Ph 1???

👍️0

HANUMAN 10月前

Wrong about P-1 testing. See today's PR regarding the NEJ publication.
Sana Biotechnology Announces Publication in New England Journal of Medicine of Groundbreaking Clinical Data from Transplantation Without Immunosuppression of Hypoimmune-Modified, Insulin-Producing Islet Cells in Patient with Type 1 Diabetes •

As far as I know, they are mid-way through P-1. Should finish near the end of the year. If results are as good as the 6 month result, this will take quite a big jump. Plus, it's potential for many other medical uses is staggering.

👍️ 2

Zadie420 10月前

Hey folks- I found this stock thru my phone advertisement. I don't know anything about this company. I am reading the news they are working on drugs that treats Diabetic I disease, CEO said they got very good results in 6 months period. what kind of trial they are running and when do they expect the results to be published. Tia

👍️0

Mojocash 11月前

37 million short cover to go! Weeeee!

👍 2

HANUMAN 11月前

When is the purpose of your posts?by the way, I was mistaken in my prior post. Sana is half way through p-1.

Hard to believe this company appears to have the cure for type 1 diabetes and it is just above $4. Shares are more than 80% owned by funds. Retail buyers haven't realized the potential here, althougt it will be a 2+ year hold. Waiting for the p1 announcement.

Steve Harr just presented at Jefferies Global Healthcare Conference on June 4 2025. Basically, the presentation asserted that the company's efforts are bearing fruit according to expectation. He clearly acknowledges that additional funding will be necessary but that has been no secret and is typical of biotech startups. The most interesting items were that Sana (1) will be presenting 6 months results on its SC451 project outcomes on June 23 and (2) expects to have a major journal article published around these results before long. If the six month results are in line with the already published 4,8, and 12 week results, this could be significant. All and all, I was impressed by Harr's command of the facts. For the most part he was able to make the science clear and understandable although he seemed a little blurry when talking about the CAR process. All and all I was impressed by the presentation. It came off as long on fact and short on hype. Sana is a speculation, no doubt. As such, it could go to zero, it could also do quite well.

Lot's of trading voodoo here. Million dollar exchanges not budging the price. Hmmm

👍 1

Gator44 1年前

Chief Scientist very confident...

👍 1

PonkenPlonken 1年前

already looking good!
Love SANA - looks like t1d CURE - believe it will become a cult stock soon. Right now the naysayers are asking why children wouldnt want to live with needles...
stock should be 6$ even with financing overhang

👍 2

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Sana Biotechnology Inc (SANA)

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

Sana Biotechnology Inc (SANA) ニュース

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Sana Biotechnology to Present at June 2026 Investor Conferences

Form 8-K - Current report

Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates

Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference

Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

SANA Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Sana Biotechnology Inc (SANA)

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

Sana Biotechnology Inc (SANA) ニュース

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Sana Biotechnology to Present at June 2026 Investor Conferences

Form 8-K - Current report

Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates

Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference

Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

SANA Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

無料で登録してください:

広告を削除する